Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

Summary

The goal of this clinical trial is to investigate the safety of rituximab for management of immune-related adverse events in malignant melanoma patients. The main questions it aims to answer are: * Is rituximab safe for management of immune-related adverse events in malingnant melanoma patients? * Does rituximab provide indications of clinical benefit in the management of immune-related adverse events compared with corticosteroid treatment alone? Participants will: * Receive a single dose of 100 mg rituximab IV * Have regular follow-up consultations for 6 months following rituximab infusion * Follow a simultaneous corticosteroid tapering plan

Timeline

Start

2026-08-01

Primary completion

2028-08-01

Completion

2028-12-01

Drugs

Indications

No indication recorded.